Showing results (171-180 of 240) with videos related to
Sort By:
Pageof 24
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2010
Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantationStefania Coppoletta, Elisabetta Tedone, Barbara Galano, et al.Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, et al.Cancers|November 13, 2021
Droplet Digital PCR for <i>BCR-ABL1</i> Monitoring in Diagnostic Routine: Ready to Start?Maria Teresa Bochicchio, Jessica Petiti, Paola Berchialla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.Haematologica|June 11, 2010
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working PartyIlaria Iacobucci, Annalisa Lonetti, Francesca Paoloni, et al.British Journal of Haematology|April 12, 2013
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapyGuido Finazzi, Alessandro M Vannucchi, Vincenzo Martinelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatmentIlaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.Blood|June 12, 2004
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)Laurent Garderet, Myriam Labopin, Norbert-Claude Gorin, et al.Pageof 24